Karyopharm Therapeutics reported $1.14M in Cost of Sales for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
TG Therapeutics TGTX:US 148K 9K
Abbott ABT:US $ 4947M 547M
Abbvie ABBV:US $ 4499M 307M
Amgen AMGN:US $ 1637M 147M
Astrazeneca AZN:US 2.19B 273M
AstraZeneca AZN:LN 2193M 273M
Biocryst Pharmaceuticals BCRX:US $ 0.34M 5.54M
Bristol Myers Squibb BMY:US $ 2451M 52M
Eli Lilly And LLY:US $ 1953.2M 74.6M
Epizyme EPZM:US $ 2.49M 361K
GlaxoSmithKline GSK:LN 2519M 108M
Johnson & Johnson JNJ:US $ 7587M 551M
Karyopharm Therapeutics KPTI:US $ 1.14M 205K
MacroGenics MGNX:US 22K 5K
Merk MRK:US $ 2684M 771M
Nektar Therapeutics NKTR:US $ 7.67M 1.91M
Novartis NOVN:VX SF 3754M 79M
Novartis NVS:US $ 3754M 79M
Pfizer PFE:US $ 6992M 2820M
Regeneron Pharmaceuticals REGN:US $ 693.7M 385.7M
Takeda 4502:JP Y 241264M 12182M
Ultragenyx Pharmaceutical RARE:US $ 3.14M 2.05M
YTE INCY:US $ 32.63M 8.81M